Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL933349 | 0.83 | CYP3A4 (0.62) | CYP1A2CYP3A4ALDH1A1ADRA2AKMT2A | |
| SCHEMBL6264784 | 0.83 | CYP3A4 (0.62) | CYP1A2CYP3A4ALDH1A1ADRA2AKMT2A | |
| Hydrochloric Acid SCHEMBL28672927 | 0.81 | CYP3A4 (0.60) | CYP1A2CYP3A4ALDH1A1ADRA2AKMT2A | |
| Hydrogen Sulfide SCHEMBL8052104 | 0.81 | CYP3A4 (0.60) | CYP1A2CYP3A4ALDH1A1ADRA2AKMT2A | |
| SCHEMBL27536605 | 0.81 | CYP1A2 (0.64) | CYP1A2CYP3A4ALDH1A1ADRA2AKMT2A | |
| SCHEMBL10893337 | 0.80 | LMNA (0.55) | CYP1A2CYP3A4ALDH1A1KMT2ASLC6A3 | |
| SCHEMBL3289319 | 0.79 | CYP3A4 (0.62) | CYP1A2CYP3A4ALDH1A1ADRA2AKCNH2 | |
| SCHEMBL6510710 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP3A4ALDH1A1ADRA2AKMT2A | |
| SCHEMBL15942047 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP3A4ALDH1A1ADRA2AKMT2A | |
| SCHEMBL28116116 | 0.79 | CYP1A2 (0.53) | CYP1A2CYP3A4ALDH1A1ADRA2AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9035065-B2 | Ethanamine compounds and methods of using the same | ASTRAZENECA AB (SE) | 2015-05-19 | — | — | US | disclosed |
| US-9035065-B2 | Ethanamine compounds and methods of using the same | ASTRAZENECA AB (SE) | 2015-05-19 | — | — | US | disclosed |
| US-9035065-B2 | Ethanamine compounds and methods of using the same | ASTRAZENECA AB (SE) | 2015-05-19 | — | — | US | disclosed |
| EP-2610246-A1 | Ethanamine compounds and methods of using the same | AstraZeneca AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| EP-2610246-A1 | Ethanamine compounds and methods of using the same | AstraZeneca AB (SE) | 2013-07-03 | — | — | EP | disclosed |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2013-05-30 | — | — | US | disclosed |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2013-05-30 | — | — | US | disclosed |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | ASTRAZENECA AB (SE) | 2013-05-30 | — | — | US | disclosed |
| US-20120277272-A1 | Ethanamine Compounds and Methods of Using the Same | ASTRAZENECA AB (SE) | 2012-11-01 | — | — | US | disclosed |
| US-20120277272-A1 | Ethanamine Compounds and Methods of Using the Same | ASTRAZENECA AB (SE) | 2012-11-01 | — | — | US | disclosed |
| US-20120115913-A1 | Ethanamine Compounds and Methods of Using the Same | BALESTRA MICHAEL (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115913-A1 | Ethanamine Compounds and Methods of Using the Same | BALESTRA MICHAEL (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2391606-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | AstraZeneca AB (SE) | 2011-12-07 | — | — | EP | disclosed |
| US-8013165-B2 | Ethanamine compounds and methods of using the same 545 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8013165-B2 | Ethanamine compounds and methods of using the same 545 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-8013165-B2 | Ethanamine compounds and methods of using the same 545 | ASTRAZENECA AB (SE) | 2011-09-06 | — | — | US | disclosed |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | ASTRAZENECA AB (SE) | 2010-07-15 | — | — | US | disclosed |
| WO-2010074647-A1 | ETHANAMINE COMPOUNDS AND THEIR USE FOR TREATING DEPRESSION | ASTRAZENECA AB (SE) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115913-A1 | Ethanamine Compounds and Methods of Using the Same | PNMT, HTR5A, TPH2 | CYP1A2 268/4885CYP3A4 387/4885ALDH1A1 517/4885 |
| US-20120277272-A1 | Ethanamine Compounds and Methods of Using the Same | PNMT, TPH1, TPH2 | CYP1A2 1162/4885CYP3A4 2159/4885ALDH1A1 802/4885 |
| US-20130137731-A1 | ETHANAMINE COMPOUNDS AND METHODS OF USING THE SAME | TPH1, TPH2, PNMT | CYP1A2 355/4885CYP3A4 458/4885ALDH1A1 548/4885 |
| US-20100179199-A1 | Ethanamine Compounds and Methods of Using the Same 545 | HTR5A, PNMT, GRIK5 | CYP1A2 380/4885CYP3A4 357/4885ALDH1A1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.